REGN
Price:
$609.94
Market Cap:
$62.84B
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally...[Read more]
Industry
Biotechnology
IPO Date
1991-04-02
Stock Exchange
NASDAQ
Ticker
REGN
According to Regeneron Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 14.90. This represents a change of -16.09% compared to the average of 17.76 of the last 4 quarters.
The mean historical PE Ratio of Regeneron Pharmaceuticals, Inc. over the last ten years is 21.31. The current 14.90 PE Ratio has changed 6.89% with respect to the historical average. Over the past ten years (40 quarters), REGN's PE Ratio was at its highest in in the December 2017 quarter at 58.02. The PE Ratio was at its lowest in in the June 2021 quarter at 4.73.
Average
21.31
Median
17.87
Minimum
8.27
Maximum
42.93
Discovering the peaks and valleys of Regeneron Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 115.46%
Maximum Annual PE Ratio = 42.93
Minimum Annual Increase = -51.20%
Minimum Annual PE Ratio = 8.27
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 17.92 | 2.90% |
| 2024 | 17.42 | -26.53% |
| 2023 | 23.71 | 33.10% |
| 2022 | 17.81 | 115.46% |
| 2021 | 8.27 | -44.14% |
| 2020 | 14.80 | -23.63% |
| 2019 | 19.37 | 10.44% |
| 2018 | 17.54 | -47.41% |
| 2017 | 33.36 | -22.30% |
| 2016 | 42.93 | -51.20% |
The current PE Ratio of Regeneron Pharmaceuticals, Inc. (REGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
19.68
5-year avg
17.02
10-year avg
21.31
Regeneron Pharmaceuticals, Inc.’s PE Ratio is greater than Cigna Corporation (11.77), less than Elevance Health Inc. (16.52), less than Alnylam Pharmaceuticals, Inc. (63.78), greater than Zoetis Inc. (12.57), less than Cencora, Inc. (20.72), less than argenx SE (49.74), less than Genmab A/S (18.89), less than IDEXX Laboratories, Inc. (41.12), greater than Incyte Corporation (13.45), less than United Therapeutics Corporation (18.33),
| Company | PE Ratio | Market cap |
|---|---|---|
| 11.77 | $73.88B | |
| 16.52 | $84.37B | |
| 63.78 | $37.13B | |
| 12.57 | $33.00B | |
| 20.72 | $52.89B | |
| 49.74 | $54.32B | |
| 18.89 | $15.51B | |
| 41.12 | $44.34B | |
| 13.45 | $19.62B | |
| 18.33 | $22.78B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regeneron Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Regeneron Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Regeneron Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Regeneron Pharmaceuticals, Inc. (REGN)?
What is the highest PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?
What is the 3-year average PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?
What is the 5-year average PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN)?
How does the current PE Ratio for Regeneron Pharmaceuticals, Inc. (REGN) compare to its historical average?